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Some breast cancers have been shown to contain a small fraction of
cells characterized by CD44/CD24/low cell-surface antigen profile
that have high tumor-initiating potential. In addition, breast cancer
cells propagated in vitro as mammospheres (MSs) have also been
shown to be enriched for cells capable of self-renewal. In this study,
we have defined a gene expression signature common to both
CD44/CD24/low and MS-forming cells. To examine its clinical sig-
nificance, we determined whether tumor cells surviving after con-
ventional treatments were enriched for cells bearing this CD44/
CD24/low-MS signature. The CD44/CD24/low-MS signature was
found mainly in human breast tumors of the recently identified
‘‘claudin-low’’ molecular subtype, which is characterized by expres-
sion of many epithelial-mesenchymal-transition (EMT)-associated
genes. Both CD44/CD24/low-MS and claudin-low signatures were
more pronounced in tumor tissue remaining after either endocrine
therapy (letrozole) or chemotherapy (docetaxel), consistent with the
selective survival of tumor-initiating cells posttreatment. We con-
firmed an increased expression of mesenchymal markers, including
vimentin (VIM) in cytokeratin-positive epithelial cells metal-
loproteinase 2 (MMP2), in two separate sets of postletrozole vs.
pretreatment specimens. Taken together, these data provide sup-
porting evidence that the residual breast tumor cell populations
surviving after conventional treatment may be enriched for subpopu-
lations of cells with both tumor-initiating and mesenchymal features.
Targeting proteins involved in EMT may provide a therapeutic strat-
egy for eliminating surviving cells to prevent recurrence and improve
long-term survival in breast cancer patients.
CD44/CD24/low markers  gene expression signature 
tumor-initiating cancer cells  mesenchymal features  treatment resistance
Despite recent improvements in breast cancer mortality, manypatients relapse after an initial response to conventional
endocrine therapy and chemotherapies. Several alternative but not
necessarily mutually exclusive hypotheses have been proposed to
explain this treatment failure and recurrence. In particular, it has
been suggested that a small subpopulation of cells within tumors,
often designated as ‘‘tumor-initiating cells’’ or ‘‘cancer stem cells,’’
may be resistant to therapy and hence may reinitiate tumor growth
after treatment (1). The population containing these cells can be
isolated by FACS using specific cell surface markers. For example,
in cells from metastatic pleural effusions, the CD44/CD24/low/
lineage subpopulation was shown to be enriched for tumor-
initiating cells (2). Recently, we have reported that this CD44/
CD24/lowsubpopulation of cells appears to be more relatively
resistant to chemotherapy in paired primary human breast cancer
biopsies (3). This increase was associated with an enhanced mam-
mosphere (MS)-forming ability, an in vitro surrogate assay of
self-renewal capacity (3).
Global gene expression analyses have identified at least four
major subtypes of human breast cancers (luminal A/B, basal-like,
and ERBB2-enriched) (4, 5). More recently Herschkowitz et al. (6)
described another subtype, involving relatively uncommon breast
cancers, termed ‘‘claudin-low,’’ which are characterized by com-
paratively high expression of mesenchymal markers such as vimen-
tin and low expression of epithelial markers, notably claudins and
E-cadherin. During the course of normal development, the trans-
differentiation of epithelial cells to a more mesenchymal state
(7–13) known as epithelial-to-mesenchymal transition (EMT), is an
essential process; this process has also been implicated in cancer
progression (14). Indeed, an increased representation after therapy
of cancer cells expressing mesenchymal markers, notably those
described in claudin-low tumors, may account for treatment resis-
tance (15–17). It is not known directly at this time whether the
claudin-low tumors show elevated resistance to therapy.
Defining the regulatory pathways in subpopulations of residual
tumor cells that survive conventional therapy could ultimately provide
important new therapeutic targets. With this objective in mind, we first
derived a gene signature from CD44/CD24/low/lineage cells and
formed cancer MS cells, both isolated from human breast cancers. We
then compared this CD44/CD24/low-MS signature to the previously
defined intrinsic subtypes of breast cancer to determine whether there
was any subtype that was highly enriched for this subpopulation. To
examine the signature’s clinical and therapeutic significance, we eval-
uated it in breast tumors before and after therapy (letrozole or
docetaxel), doing so with the hypothesis that the tumor cells surviving
after treatment would have an increased expression of the CD44/
CD24/low-MS signature. Finally, relevant key markers from this sig-
nature were confirmed in additional paired before and after treatment
patient specimens.
Results
Gene Transcription Patterns in Breast Cancer Cells with Tumor-Initi-
ating Potential. To define a gene expression signature, we used two
methods to obtain breast cancer subpopulations that have been
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suggested previously to be enriched for putative tumor-initiating
cells: CD44/CD24/low markers and formed cancer MSs (2). These
analyses involved 36 tumors representing all subtypes of breast
cancer (18 luminal A/B, 13 basal-like, and 5 ERBB2-enriched) (Fig.
S1). We performed comparative gene expression profiling in the
populations that have been shown by others to be enriched for
tumor-initiating cells (CD44/CD24/low or formed cancer MSs) vs.
non-tumor-initiating cells (all ‘‘other’’ flow-sorted fractions or bulk
tumor, respectively), and then analyzed to look for significant
overlap between the gene expression patterns of cells isolated by the
two alternative enrichment methods.
In the first comparison (consisting of 14 CD44/CD24/low vs. 15
other profiles, representing 20 patients including nine patient pairs),
2,221 RNA transcripts (1,424 named genes) were elevated (P  0.01
unpaired, two-sided t test; fold change 1.5; FDR 0.2) in the
flow-sorted CD44/CD24/low vs. other cells. In the second com-
parison (consisting of 15 MS vs. 11 primary cancer profiles, repre-
senting 16 patients including 10 patient pairs), 2,696 transcripts
(1,890 named genes) were elevated (P  0.01 unpaired, two-sided
t test; fold change 1.5; FDR 0.25) in the MSs vs. primary cancers.
The numbers of elevated genes appearing in both of the enrichment
methods exceeded the chance overlap expected (P  1E  5,
one-sided Fisher’s exact test) (Fig. 1A, Fig. S2A, and SI Text).
Between the transcripts with decreased expression, 339 transcripts
(263 genes) significantly overlapped (P  1E  15, one-sided
Fisher’s exact test) (Fig. 1B, Fig. S2B, and SI Text). Therefore, we
defined here a ‘‘CD44/CD24/low-MS gene signature’’ which
comprised the relative ‘‘up’’ and ‘‘down’’ patterns of the 493
transcripts (154 overexpressed and 339 underexpressed) present in
the significant overlap between both comparisons (heat map in Fig.
1C, complete gene list in Dataset S1).
The CD44/CD24/low-MS Signature Is Enriched in Human Breast Tu-
mors of the Claudin-Low Molecular Subtype. Most human breast
cancers can be robustly classified into one of the intrinsic subtypes:
luminal A and B, HER2-enriched, basal-like, and claudin-low (4–6).
The claudin-low subtype identified by Herschkowitz et al. (6) is char-
acterized by the high expression of mesenchymal genes and the low
expression of cell–cell contact genes, such as claudins 3, 4, and 7, and
E-cadherin.WecomparedtheCD44/CD24/low-MSsignature toeach
subtype to determine whether any group showed enrichment. For each
tumor in the Herschkowitz dataset, we derived an ‘‘R value’’ in relation
to our CD44/CD24/low-MS signature, with the R value being a
measure forhowmucheach individualHerschkowitz tumormanifested
our signature (see Methods).
Only the previously defined claudin-low group showed a clear
association with the CD44/CD24/low-MS signature (Fig. 2A). We
obtained the same results using a number of other analytical
approaches, including one-sided Fisher’s exact tests and GSEA (see
SI Text and Fig. S3). Furthermore, relative to the other tumors,
claudin-low tumors showed low mRNA expression of CD24 and
high mRNA expression of CD44 (Fig. 2B), consistent with the
notion that these tumors are enriched for tumor-initiating cells
bearing these markers. The above correlation patterns were further
evident when viewing a heat map of the genes in the CD44/
CD24/low-MS signature within the published Herschkowitz data-
set (Fig. 2C).
CD44/CD24/low-MS and Claudin-Low Gene Signatures Are Enriched
in Human Breast Tumors After Treatment with Endocrine Therapy or
Chemotherapy. We have reported that breast cancers after chemother-
apy are enriched for CD44/CD24/low-MS cells by flow cytometric
analysis (3). In that earlier study, postchemotherapy specimens showed
an increase in cells bearing CD44/CD24/low and an increase in
MS-forming efficiency (3). If tumor-initiating cells are resistant to
chemotherapy and endocrine therapy, then we would expect to see
strong enrichment of the CD44/CD24/low-MS signature in both the
endocrine- and chemotherapy-treated residual tumors. We tested this
notion in two datasets. First, we profiled 36 ER-positive human breast
tumors from patients receiving neoadjuvant endocrine therapy; these
represented 18 patient pairs before and after treatment (3 months) with
the aromatase inhibitor letrozole. We computed an R value in relation
to the CD44/CD24/low-MS signature pattern, to measure the degree
of signature enrichment (see SI Text and Fig. S4). The letrozole
posttreatment tumors had higher R values than the pretreatment
tumors (P  0.01, paired t test) (Fig. 3A).
Next, we examined our published dataset of predocetaxel and
postdocetaxel treatment, representing 12 patient pairs (18, 19).
Fig. 1. A gene transcription signature of
breast cancer cells with putative tumor-
initiating potential. (A) Venn diagram of the
intersection between genes elevated in can-
cer mammospheres (MSs, rich in CD44/
CD24/low cells) compared with primary can-
cers and genes elevated in CD44/CD24/low
cells obtained from FACS assay (P  0.01, fold
change 1.5 for each comparison). P value for
the overlap between the two gene sets by
one-sided Fisher’s exact test. (B) As with A but
for genes lower in cancer MSs and genes
lower in CD44/CD24/low flow-sorted cells.
(C) Heat map of genes in the CD44/CD24/
low-MS signature (from parts A and B). Each
row represents a transcript; each column, a
sample (yellow: high expression). Associations
of the genes with selected Gene Ontology
(GO) annotation terms are indicated. Genes in
the indicated region are listed by name.








Again, we found that postdocetaxel tumors had higher correlations
with the CD44/CD24/low-MS signature (P  0.01, paired t test)
(Fig. 3B). Thus, the CD44/CD24/low-MS signature was increased
after either chemotherapy or endocrine therapy. Similarly, the
claudin-low patterns were increased in posttreated compared with
pretreated tumors in both the letrozole and docetaxel cohorts
(P  0.001 and P  0.01, respectively, comparing R values by
paired t test) (Fig. 3 C and D). We also examined the CD44/
CD24/low-MS signature as heat maps in both the letrozole-treated
and claudin-low samples (Fig. 3E). We found that the overlapping
patterns between the letrozole treatment signature and our CD44/
CD24/low-MS signature were significant by both one-sided Fisher’s
exact tests and GSEA (SI Text). Likewise, the overlap between the
letrozole-treated tumors and the CD44/CD24/low-MS signature
was largely shared by the claudin-low tumors in the heat map
representation (Fig. 3E). Notably, all of the claudin-low tumors in
the Herschkowitz dataset had been sampled from patients before
therapy, yet this claudin-low profile was more evident after therapy.
Mesenchymal-Associated Genes Are Increased in Postletrozole
Breast Cancer Specimens. The association between the CD44/
CD24/low-MS signature and the claudin-low subtype suggests that
residual tumor cells may display mesenchymal features. We there-
fore examined a number of mesenchymal markers described in a
literature review (20) and found that, as predicted, a number of
these markers were elevated (FN1, SNAI2, VIM, FOXC2, MMP2,
and MMP3) or diminished (CDH1 and DSP) at the RNA level in
the cancer MSs vs. primary bulk tumor (Fig. 4A). The overlap
between the mesenchymal up genes (20) and the cancer MS up
genes was statistically significant (P  0.001, one-sided Fisher’s
exact test). These patterns were not as clearly evident in the
CD44/CD24/low vs. other flow sort profile dataset, with only
some mesenchymal genes elevated (VIM) or decreased (CDH1 and
DSP) significantly (Fig. 4A).
We next analyzed the expression of a number of these identified
mesenchymal genes (VIM, E-cadherin, and MMP2) in additional
paired letrozole-treated breast cancer specimens. We selected these
markers based on the availability of commercial antibodies and
established methods for detecting them. Protein validation of
additional genes like SNAI2 was not performed, because proce-
dures for detecting these by immunohistochemistry of these gene
products had not been established. We performed immunoflores-
cence analysis of the mesenchymal gene vimentin (red) with the
epithelial pan-cytokeratin marker (green). A subset of tumor
epithelial cells postletrozole were both cytokeratin and vimentin
positive (Fig. 4B), suggesting that these may represent epithelial
cancer cells that have acquired some mesenchymal features.
To quantify this apparent increase in mesenchymal properties in
epithelial cells, we performed automated quantitative analysis
(AQUA) of vimentin expression in the epithelial compartments of
the tumor in 26 paired patient samples that were delineated by
its/their cytokeratin expression. The percentage of vimentin/CK
double-positive cells in biopsies taken before vs. after letrozole
treatment showed a statistically significant increase (P  0.034,
paired t test) (Fig. 4C). The expected decrease in expression of
E-cadherin was not observed in postletrozole treated specimens,
possibly because of the difficulty in quantifying decreases in bi-
omarker expression by immunohistochemistry (IHC) in tumors
with low baseline values. In addition, we quantified RNA levels by
quantitative reverse transcription PCR for MMP2 in tumors before
and after letrozole therapy from 60 patients, and showed an
increased expression both at 10–14 days and at 3 months (P 
0.0001 and P  0.00001, respectively, paired t test) (Fig. 4D).
Discussion
The present work has led to the identification of a unique molecular
signature of therapy-resistant CD44/CD24/low-MS cells. We de-
rived our signature by using two published enrichment methods for
putative tumor-initiating cells (2): flow cytometric sorting for
selected markers (CD44/CD24/low) and a biological functional
assay for self-renewal (formed cancer MSs). Our previous study
showed an increase in the CD44/24/low cell population by flow
Fig. 2. The CD44/CD24/low-MS gene signa-
ture is enriched in human breast tumors of the
claudin-low molecular subtype. (A) Correlation
(R value, see Methods) between the CD44/
CD24/low-MS signature pattern and each tu-
mor in the gene expression profile dataset by
Herschkowitz et al. (6) (claudin-low, basal,
ERBB2, luminal, normal-like; averages cen-
tered on the mean centroid of the groups). R
values above red dotted line are significant at
P  0.00001. (B) Scatter plot of CD24 versus
CD44 mRNA expression for the Herschkowitz
tumors. (C) Heat map of the corresponding pat-
terns of the CD44/CD24/low-MS signature
genes within the Herschkowitz tumors. The or-
der of the Herschkowitz tumors is the same for
A and C; the order of the genes is the same
across datasets.
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cytometric analysis in primary cancers surviving neoadjuvant
chemotherapy, which was associated with an increase in mammo-
sphere-forming ability and an increase in xenograft outgrowths in
immunocompromised mice; the latter measurement, however, was
not statistically significant (3). In the present study, we demonstrate
a far stronger manifestation of the CD44/CD24/low-MS signature
after both neoadjuvant chemotherapy, and endocrine therapy.
Taken together, these data provide evidence that residual after
conventional treatment breast tumors are enriched for cells exhib-
iting both tumor-initiating and mesenchymal features. The gene
expression patterns of the CD44/CD24/low-MS cells showed
significant correlation with the subtype of breast cancers classified
as claudin-low, which have been found to exhibit up-regulation of
mesenchymal genes (6). One possible explanation of this correla-
tion is that conventional therapies yield tumors that are enriched for
‘‘tumor-initiating’’ cells, which may be more resistant to these
treatments (3); accordingly, the tumor cells surviving treatment also
show more mesenchymal-like features that are characteristic of the
cells in claudin-low tumors.
Alternatively, it is possible that stromal reactions to therapy result
in an increase in tumor-associated cells expressing mesenchymal
genes. This appears to be less likely, because the samples analyzed
here were obtained from women who received a variety of treat-
ments, including both chemotherapy and endocrine treatments.
Whereas the claudin-low tumors described by Herschkowitz et al.
analyzed tumors prepared from patients before therapy, our own
data indicate that cells having a similar profile are more evident
after therapy. The mechanistic basis for these observations has yet
to be determined. Because the claudin-low tumors have only been
just described, it is not known whether this subtype is more or less
resistant to conventional therapy. However, a recent paper de-
scribed similarities in gene expression patterns between metaplastic
cancers and the ‘‘claudin low’’ subtype; metaplastic cancers are
known to be more resistant to conventional chemotherapy (18).
As mentioned, studies have identified increased mesenchymal
features in basal-like breast cancers (19). These studies in cell lines
have suggested that the switch to a mesenchymal phenotype might
be related to the aggressiveness and metastatic spread of tumors. In
this regard, one of the genes elevated in the CD44/CD24/low-MS
signature, FOXC2, has been suggested to play a key role in
orchestrating this mesenchymal phenotype (20). Recently, the same
authors noted that induction of EMT in immortalized human
mammary epithelial cells resulted in the acquisition of mesenchy-
mal traits and expression of stem-cell markers (21). Our current
observations suggest that the residual tumor cells surviving after
therapy may also display mesenchymal features in human clinical
specimens. The association of the mesenchymal phenotype with
treatment resistance has been inferred by several articles describing
the association between resistance to endocrine therapy (tamox-
ifen) (22) and chemotherapy (oxaliplatin, paclitaxel, and others)
and a mesenchymal phenotype (15–17). Here, we provide clinical
evidence that markers of the mesenchymal phenotype, assessed by
both protein and gene expression, are higher in tumors after
chemotherapy and endocrine therapy.
These data support a growing body of evidence for a mesenchy-
mal-like phenotype in some breast cancers that may be responsible
for invasion, metastasis, and possibly, treatment resistance (15–17).
In addition, recent evidence indicates that CD44, whose positive
expression selects for tumor-initiating cells, may be important in
cancer cell proliferation, migration, and metastasis (23). Our results
Fig. 3. The CD44/CD24/low-MS gene signa-
ture is enriched in a subset of human breast
tumors after treatment with hormone therapy
or chemotherapy. (A) Correlation between the
CD44/CD24/low-MS signature pattern and
each of 36 human breast tumor profiles, repre-
senting 18 pairs before and after treatment
with letrozole. R values above red dotted line
are significant at P  0.01. (B) Correlation be-
tween the CD44/CD24/low-MS signature pat-
ternandeachof24tumorprofiles, representing
12 pairs before and after treatment with
docetaxel. (C) Heat map of the correlations be-
tween each letrozole-treated tumor profile
(part A) and the average expression for each of
the four major Herschkowitz molecular tumor
profile subtypes (claudin-low, basal, ERBB2,
luminal; averages centered on the mean cen-
troid of the groups). P value comparing pre-
treatment and posttreatment R values for the
claudin-low group by paired t test. (D) As with
part C, but for the docetaxel-treated tumors (B).
(E) Heat maps of the corresponding patterns of
the CD44/CD24/low-MS signature genes
within the letrozole posttreatment tumors
(each tumor centered on corresponding pre-
treatment pair) and the Herschkowitz claudin-
low tumors (centered on mean centroid of
tumor groups). Gene ordering is the same
across datasets.








demonstrate that these residual tumors after various treatments
also display increased expression of some mesenchymal markers.
The future challenge will be to use our CD44/24/low cell-MS gene
signature to select the most relevant targets to combine with
conventional therapy to overcome the intrinsic resistance to therapy
of these cells.
Materials and Methods
Patients and Clinical Samples. We made the following comparisons on breast
cancer samples obtained from women undergoing clinical trials: i) flow-sorted
samples: CD44/CD24/low vs. others; ii) cancer MSs vs. primary tumors; iii) com-
parison of CD44/CD24/low-MS signature with the published Herschkowitz data-
set describing the new group of claudin-low vs. basal, luminal, ERBB2, and
normal-like tumors; iv) letrozole and docetaxel: before and after treatment to
demonstrate enrichment of the CD44/CD24/low-MS signature.
First, to generate the CD44/CD24/low-MS signature, tumor biopsies were
obtainedbeforeanytreatmentfrompatientswith locallyadvancedbreast cancer
enrolled into two phase II clinical trials (approved by the institutional review
board) fromJanuary2000toDecember2006(Figs. S1–S4).Thesetwostudieswere
conducted in the Breast Center at Baylor College of Medicine, Houston, TX.
Biopsies were obtained with informed consent for biomarker correlative studies.
Allof thecorebiopsiesused in theseanalyseswereexaminedbyH&Estainingand
determined to contain greater than or equal to 50% epithelial cancer cells before
analysis. From these two studies, we obtained microarray gene expression anal-
yses of flow-sorted samples (CD44/CD24/low vs. others) and cancer MSs vs.
primary tumor (Fig. S1), forestablishingourCD44/CD24/low-MSgenesignature.
Second, to examine the clinical and therapeutic significance of the microarray
results, we evaluated the gene expression profile in additional breast tumors
before and after therapy. For these analyses, there were three patient cohorts,
‘‘letrozole,’’ ‘‘docetaxel,’’ and ‘‘additional letrozole,’’ as follows. In the first, the
letrozole cohort, RNAs were provided from biopsies from postmenopausal pa-
tients with ER-positive breast cancers treated with neoadjuvant aromatase in-
hibitor letrozole for 12 weeks. This study was conducted at Western General
Hospital, Edinburgh, U.K. In the second, the docetaxel cohort, we used our
published analysis of differentially expressed genes before and after docetaxel
(24, 25). The third, the additional letrozole cohort, also from Edinburgh, was used
to validate certain results by immunohistochemistry on formalin-fixed sections of
a further series of paired letrozole-treated samples (before and after 12 weeks of
letrozole). There were 23 pairs of samples with sufficient tissue for IHC, where we
analyzed costaining of the epithelial marker pan-cytokeratin (CK) together with
the mesenchymal marker vimentin (VIM), and loss of E-cadherin staining. In an
earlier analysis, we performed QRT-PCR for MMP2 gene expression in paired
biopsies from 60 patients before and after letrozole treatment (26).
Analytical Flow Cytometry and MSs. Core biopsies were taken before and after
treatment, and placed immediately in cold RPMI-1640 supplemented with 10%
heat-inactivated newborn calf serum (HINCS, Invitrogen). The methods for flow
cytometry and mammosphere growth have been described in detail elsewhere
(3). In summary, the samples were digested in collagenase and 106 single cells
were resuspended, incubated for 15 min with anti-CD44 (APC), anti-CD24, and
anti-lineage mixture antibodies (PE-conjugated anti-CD2, CD3, CD10, CD16,
CD18, CD31, and CD 140B) (PharMingen) using the manufacturer’s suggested
concentrations, and then analyzed using Dako MoFlo flow cytometry. Side and
forward scatter were used to eliminate debris and cell doublets, and the Lin cells
were further analyzed for expression of the CD44 and CD24 markers. A portion
of the unsorted cells was used in MS assays by plating these cells onto nonadher-
ent (polyhema-coated) plastic, counting with a hemocytometer, and seeding
20,000 cells into six-well ultralow attachment plates.
Gene Expression Profiling. RNA was purified from sorted CD44/CD24/low cells
vs. all others (CD24 and CD44/CD24), cancer-derived MSs vs. primary breast
Fig. 4. Specific markers of mesenchymal
cells are overexpressed in both CD44/
CD24/low-MS cells and letrozole-treated pa-
tient tumors. (A) For the flow sort and cancer
MS profile datasets, heat map of previously
associated mesenchymal genes in a review by
Lee et al. (31) (genes in bold, significant with
P  0.01; the entire set of mesenchymal-
associated proteins from the review that we
couldmaptospecificgenes inourdatasetare
represented). (B) Protein expression of vi-
mentin and pan-cytokeratin (CK) in a patient
tumor after letrozole treatment. (C) Immu-
nofluorescenceanalysisofvimentin (red)and
pan-cytokeratin(green)afterchemotherapy.
Yellow arrows mark double-positive cells,
whereas red and green arrows mark vimen-
tin and CK positive epithelial cells, respec-
tively. (D) MMP2mRNA levels in tumors be-
fore and after letrozole. (P values in B and C
by paired t test).
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cancer,andbeforeandafter treatmentwith3monthsof letrozole foruse ingene
expressionprofiling,asdescribed inrefs.24and25.Briefly, totalRNAwas isolated
using TRIzol (Invitrogen) and passed over a Qiagen RNeasy column (Qiagen).
Double-stranded cDNA was synthesized by a chimeric oligonucleotide with an
oligo(dT) and a T7 RNA polymerase promoter. Reverse transcription was then
carried out, followed by biotin labeling and an 250-fold linear amplification by
in vitro transcription (Enzo Biochem). From each sample, 5 g of labeled cRNA
was hybridized onto an Affymetrix U133 Plus2 GeneChip.
IHC, AQUA, and Real-Time PCR (qPCR) Analysis. Standard methods for immuno-
histochemical analysis have been described in detail elsewhere (27). All slides
werescoredbytwopathologists (M.C.G.andD.R.)blindedtothetreatmentstatus
(before vs. after treatment). For immunofluorescence, 4-m paraffin-embedded
formalin-fixed tumor biopsies were incubated with antibodies against vimentin
(dilution, 1:250; AB-1 Clone V9, Oncogene Research Products) and pan-keratin
(dilution, 1:100; polyclonal, Signet) for 1 h at room temperature, followed by
secondary antibodies conjugated to Alexafluor 594 and 488, respectively, for 30
min. Slides were mounted in Vectashield Mounting Media containing DAPI
(Vector Laboratories) for nuclear staining.
For quantitative analysis of vimentin, we performed AQUA analysis as de-
scribed in ref. 28. In brief, a tumor-specific mask was generated by thresholding
the image of a marker (cytokeratin) that differentiates tumor from surrounding
stroma and/or leukocytes. This creates a binary mask (each pixel is either on or
off). In this study, total signal nuclear, cytoplasmic, and the ratio of nuclear to
cytoplasmic signal were analyzed. Scores were adjusted according to amount of
area covered by the subcellular compartments within the masked area. Histo-
spots containing 5% tumor, by mask area (automated), were excluded from
further analysis. AQUA scores were normalized on a 0 to 100 scale for each cohort
by dividing by the maximum AQUA score. As part of this study, we conducted
qPCR for six differentially expressed genes, including MMP2, and these data were
used as part of the validation of mesenchymal genes (Fig. 4).
Data Analysis. We normalized gene expression arrays using DNA-Chip Analyzer
software (dChip). The array data have been deposited in the public Gene Expres-
sionOmnibus (GEO)database(GSE7513,GSE7515,andGSE10281).Foreachofthe
profile datasets analyzed, we centered gene expression values on the centroid
mean of the comparison groups of interest (flow sort: CD44/CD24/low and
others; MS: cancer MS and primary tumor; Herschkowitz tumors: claudin-low,
basal, luminal, ERBB2, letrozole and docetaxel: before and after treatment). In
the case of the Herschkowitz dataset, where multiple array probe sets referred to
the same gene, we selected the probe set with the greatest variation to represent
the gene. (In the Herschkowitz et al. analysis, luminal A and B tumors were
assigned to one ‘‘luminal’’ group based on cluster analysis, and we used the
subtype labels assigned by the Herschkowitz group for our own analysis.) Two-
sided t tests using log-transformed data determined significant differences in
mean gene mRNA levels between groups of samples. We computed fold changes
between groups as in ref. 29 and estimated the false discovery rate (FDR) using
100permutationsof theprofilegroup labels. Expressionvalueswerevisualizedas
color maps using the Java TreeView software. The mapping of transcripts or
genes between independent array datasets was made on the Affymetrix probe
set identifier, in the case where both datasets were on the Affymetrix U133 Plus
2 or U133A platforms, or on the Entrez Gene identifier, in the case where the
datasets were from different platforms. We determined the significance of
overlapbetweengenesetsusingone-sidedFisher’sexact tests,withthereference
genepopulationbeingeitherthe54675U133Plus2probesetsorthe14112genes
in both U133 Plus 2 and the Herschkowitz Agilent platforms, depending on from
which array platforms the two gene sets were obtained. We also carried out gene
set enrichment analysis (GSEA) as an alternative enrichment test (see SI Text) (30).
Gene Signature R Values. To score each tumor within a set for similarity to our
gene signature, we derived an R value for each tumor in relation to the CD44/
CD24/low-MS signature, similar to what we have done in previous studies (29).
We defined the R value as the Pearson’s correlation between the CD44/CD24/
low-MS gene signature pattern (using ‘‘1’’ and ‘‘1’’, for up and down, respec-
tively) and the primary tumor’s expression values (which is essentially a t statistic
comparing the average of the up genes to the average of the down genes within
each tumor). In this way, tumors with high R values would tend to have both high
expression of many of the genes high in CD44/CD24/low-MS cells and low
expression of many of the genes that are low in CD44/CD24/low-MS cells (and
vice versa for tumors with low R values). For the human tumor datasets, the gene
expression values were first centered as described above before computing the R
value.
We then determined whether the gene expression pattern of the previously
defined claudin-low human subtype was more pronounced in the tumors after
hormone therapy or chemotherapy (Fig. 3 C and D) in the following way. For each
gene common to our array platform and the Herschkowitz platform, we com-
puted the mean centroid of the four major tumor subtypes: claudin-low, basal-
like, ERBB2, and luminal, and centered each group average on the centroid. We
then took the Pearson’s correlation (R value, using all 14,112 genes common to
both datasets) between the Herschkowitz centered averages and the expression
values of each pretreated or posttreated tumor from the letrozole and docetaxel
cohorts.
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